Laverock Therapeutics has announced new in vivo programmes spanning CAR‑T and genetic medicine, expanding its therapeutic pipeline beyond ex vivo cell therapies. The company said the move strengthens its ability to tackle major challenges in oncology and genetic disease. Its programmable gene control platform enables tunable and multiplex control of endogenous targets and transgenic payloads.
The technology has already been validated in several cell therapy applications, including armoured autologous T cells and iPSC‑derived macrophages targeting solid tumours. Laverock said its in vivo programmes will improve efficacy, safety, accessibility and scalability for CAR‑T, while supporting development across high unmet‑need indications in genetic medicine.
Solid tumours represent 90% of cancer cases, and the company believes its platform is well suited to overcoming the inhibitory factors of the tumour micro‑environment.
In genetic medicine, Laverock will use in vivo gene silencing through direct delivery of gene editing tools. This approach aims to support therapy development for nervous system disorders and metabolic disease. The company said its technology is differentiated by its ability to control multiple targets or pathways simultaneously with precision and context‑specific gene expression.
David Venables, CEO of Laverock Therapeutics, said: “Building on our success in developing ex vivo therapeutics, we are extremely excited to announce the launch of our in vivo programmes, and realise the benefits these cutting edge technologies can bring to patients.”
He added: “This area is highly innovative, and our platform can provide a key element to realising its potential.”
Laverock said industry interest is growing in therapies that can be delivered directly to patients while maintaining precision and safety. The company has several technology partnerships and is open to new collaborations.
